Galapagos acquires Cangenix, a structure-based drug discovery company
Galapagos NV (GLPG) and Cangenix Ltd announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering.
Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 pot ... more
Galapagos discovers novel class of antibiotics
Galapagos NV announced that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.Bacterial infections that ... more
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads an ... more